Ion channels have long been drug targets for various diseases, such as pain, seizures, cardiac arrhythmia, and cystic fibrosis. It is estimated that about 15% of approved drugs target ion channels. However, identifying small molecule modulators targeting specific ion channels is challenging and requires carefully constructed screening and validation methods. The increasingly widespread use of high-throughput automated electrophysiology platforms and improved instrumentation to perform patch clamp assays has facilitated more robust ion channel screening paradigms. CROs like Charles River have invested in developing specialty expertise in ion channel screening assay using these high-throughput automated platforms.

Tell Us More About Your Target/Study »

Our discovery services portfolio offers the broadest selection of ion channel and epithelial current assays, with industry-leading expertise to match and backed by laboratories equipped with state-of-the-art equipment utilizing a range of automated patch clamp instruments together with conventional electrophysiology. Our discovery teams have worked across a range of different channel types in cardiovascular, CNS, and rare diseases. We also offer profiling services and cell lines, which are validated for testing at each stage of the drug discovery process, and our experts are ready to work with you to design the right assay and interpret the results.

  • Fatty Acid Cysteamine Conjugates as Novel and Potent Autophagy Activators That Enhance the Correction of Misfolded F508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). Journal of Medicinal Chemistry. 2017, 60(1) 458-473. Abstract​.
  • Quantitative Profiling of the Effects of Vanoxerine on Human Cardiac Ion Channels and its Application to Cardiac Risk. Sci. Rep. 2015, 5, 17623. Full Text.

You may also be interested in...

Webinar Replays

Search our webinar archives to find additional trainings, educational presentations, and resources related to ion channels.

Eureka Blog Posts

Read what our experts are saying about ion channels as drug targets.